Current filters:


EU Commission closes antitrust case in Boehringer/Almirall dispute over COPD drugs


The European Commission has closed an antitrust investigation into allegations by Spain’s largest…

AlmirallBoehringer IngelheimEuropeLegalPatentsPharmaceuticalRespiratory and PulmonarySpiriva

Almirall/Forest set to file aclidinium for COPD by early 2012


Leading Spanish drugmaker Almirall and its US partner Forest Laboratories have started implementing a…

AlmirallBoehringer IngelheimForest LaboratoriesSpirivatiotropium

Almirall's nine-month profit jumps 5.3%


Leading Spanish drugmaker Almirall's net income in the first nine months of 2008 reached 132.6 million…

AlmirallForest LaboratoriesSpirivatiotropium

Almirall defies critics to progress COPD drug


Almirall, Spain's largest drugmaker, and US partner Forest Laboratories have confirmed that they plan…

AlmirallBoehringer IngelheimForest LaboratoriesSpirivatiotropium

Almirall tumbles 42% as COPD drug disappoints


Shares in Laboratorios Almirall fell to a record low after the firm presented disappointing late-stage…

AlmirallEscitalopram OxalateForest LaboratoriesLexaproNovartisSpirivatiotropium

FDA launches safety review of Boeh Ing's Spiriva as pooled analysis shows stroke risk


The US Food and Drug Adminsitration has launched a safety review of Spiriva (tiotropium), after German…

AlmirallBoehringer IngelheimPfizerSpirivatiotropium

Almirall's COPD drug aclidinium bromide is a potential jewel in the company's crown


A recent press event held by Spain's leading drugmaker Almirall saw the unveiling of the a ground-breaking…

AlmirallBoehringer IngelheimNovartisPfizerShireSpirivatiotropium

Back to top